Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome


Creative Commons License

Efe C., Ozaslan E., KAV T., Purnak T., Shorbagi A., ÖZKAYAR Ö., ...More

AUTOIMMUNITY REVIEWS, vol.11, no.5, pp.330-334, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 11 Issue: 5
  • Publication Date: 2012
  • Doi Number: 10.1016/j.autrev.2011.09.006
  • Journal Name: AUTOIMMUNITY REVIEWS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.330-334
  • Hacettepe University Affiliated: Yes

Abstract

Background and aim: The aim of the present study was to assess the efficacy and tolerability of budesonide as an alternative first line treatment option for autoimmune hepatitis (AIH) and the overlap syndrome.